At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
ALXN1840drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
In Brief
A Phase 2 clinical trial evaluating ALXN1840 for Wilson Disease. Completed, enrolled 9 participants across 3 sites in 3 countries.
Detailed Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWilson Disease
CountriesNew Zealand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedOct 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedOct 5, 2020
Enrollment StartSep 7, 2020
Primary CompletionJun 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.7 years ago
Interventions
ALXN1840drug
Administered orally as tablets.